Collaboration combines Zalgen’s leadership in hemorrhagic fevers and other tropical diseases with NOWDiagnostics’ unique ADEXUSDx® rapid test platform and GMP manufacturing capabilities

 

GERMANTOWN, Md. & SPRINGDALE, Ark.–(BUSINESS WIRE)–Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, announced that it has entered into a series of agreements with NOWDiagnostics Inc. (NOWDx), an innovator in rapid diagnostic tests (RDT), to collaborate in the development, manufacturing and commercialization of infectious disease diagnostic products.

Zalgen, NOWDiagnostics collaboration to advance development of rapid diagnostic tests for infectious disease.

Tweet this

Under the terms of the agreements, the parties will collaborate in bringing new rapid infectious disease tests to the global market, primarily using the patented NOWDx ADEXUSDx® test system. NOWDx will also manufacture existing Zalgen products, including the ReEBOV® Antigen Rapid Test for Ebola virus and the ReLASV™ Antigen Rapid Test for Lassa fever. The ReEBOV® Antigen Rapid Test for Ebola was the first RDT and the first immunoassay authorized for emergency use by the FDA for the presumptive detection of Ebola virus, and also the first listed for procurement by the World Health Organization (WHO) under the Emergency Use Assessment and Listing procedure……READ THE FULL RELEASE HERE